AI-generated from publicly available materials.Opentrons Labworks has successfully secured $40 million in a Series E funding round, aimed at enhancing its robotics and software capabilities in the life sciences sector.
The financing, led by Avego and supported by BroadOak Capital Partners, will primarily focus on advancing Opentrons' artificial intelligence and robotics systems. The company plans to leverage these funds to improve experimental execution and broaden its automation features, thereby facilitating the development of faster and more efficient laboratory protocols. This initiative will also enable Opentrons to enter new markets and enhance its integration within the laboratory automation landscape.
James Flexner from Avego highlighted the growing trend of automating experimental workflows, emphasizing the potential for Opentrons' platform to lead this shift in the industry. Opentrons' CEO, James Atwood, noted that their systems are designed for seamless AI integration, making lab automation accessible to a wider range of laboratories.
With over 11,000 robots deployed across more than 80 countries, Opentrons caters to a diverse clientele, including academic institutions and pharmaceutical companies. The recent funding will further bolster its use of AI technologies, such as Nvidia's platforms, to enhance its robotic systems, positioning Opentrons at the forefront of autonomous scientific innovation.